Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Sep;33(9):1091-4.
doi: 10.1007/s00259-006-0162-y. Epub 2006 Jun 28.

Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery

Affiliations
Clinical Trial

Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery

Domenico Rubello et al. Eur J Nucl Med Mol Imaging. 2006 Sep.

Abstract

Purpose: A prerequisite for optimum minimally invasive radio-guided surgery (MIRS) for primary hyperparathyroidism (PHPT) is the demonstration of significant uptake of (99m)Tc-sestamibi in a parathyroid adenoma (PA). The aim of this study was to evaluate the clinical role or (99m)Tc-sestamibi SPECT in selecting patients for this procedure.

Methods: Fifty-four consecutive PHPT patients were evaluated by single-session (99m)Tc-pertechnetate/(99m)Tc-sestamibi planar subtraction scintigraphy, followed by (99m)Tc-sestamibi SPECT acquisition to localise hyperfunctioning PAs and assist in planning the surgical approach.

Results: Scintigraphy showed the presence of a solitary PA in 47/54 patients (87%) and two or more PAs in four patients (7.4%); it was negative in the remaining three patients (5.6%). The overall sensitivity of (99m)Tc-sestamibi scintigraphy was 94.6%. In 7/54 patients, the PA was located deep in the para-oesophageal/paratracheal space. So far, 22 patients with scintigraphic evidence of a solitary PA (in four of whom the PA was located deep in the neck) have undergone successful MIRS using the low 37 MBq (1 mCi) (99m)Tc-sestamibi dose protocol. Intraoperative quick parathyroid hormone (QPTH) assay demonstrated a fall in all 22 patients, thus confirming successful removal of the hyperfunctioning PA. No major surgical complications were observed. After a period of follow-up ranging between 6 and 27 months (median 13 months), no case of persistent/recurrent PHPT was recorded. When comparing the parathyroid to background (P/B) ratio measured at planar and SPECT preoperative scintigraphy with that measured intraoperatively with the gamma probe, a good linear correlation was found between the SPECT and the intraoperative gamma probe measurements (r=0.89; p<0.01) but no correlation was found with planar scintigraphic data.

Conclusion: Our preliminary data suggest that measurement of the P/B ratio by means of (99m)Tc-sestamibi SPECT is more accurate in predicting the intraoperative measurements with the gamma probe. In this respect, a preoperative (99m)Tc-sestamibi SPECT acquisition should be recommended for better selection of PHPT patients in whom a MIRS approach can be offered.

PubMed Disclaimer

Comment in

References

    1. Eur J Nucl Med. 2000 Sep;27(9):1300-4 - PubMed
    1. J Nucl Med. 2003 Sep;44(9):1443-58 - PubMed
    1. J Nucl Med. 1998 Jun;39(6):1100-5 - PubMed
    1. Eur J Nucl Med. 2000 May;27(5):485-9 - PubMed
    1. J Nucl Med. 1996 May;37(5):798-804 - PubMed

Publication types

Substances

LinkOut - more resources